# US 2021/0277042 A1 · Low temperature process for the synthesis of mof carboxylate nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277042 A1
- Document ID: US20210277042A1
- Status: Published application
- Kind: A1
- Application number: 17/242,579
- Filed: 2021-04-28
- Published: 2021-09-09
- Earliest claimed: 2017-02-02
- Assignees: Centre National De La Recherche Scientifique; Universite de Versailles Saint-Quentin-en-Yvelines
- Applicants: Centre National De La Recherche Scientifique; Université De Versailles - Saint-Quentin-En-Yvelines
- Inventors: Monik PANCHAL; Farid Nouar; Christian Serre; Marvin Benzaqui; Saad Sene; Nathalie Steunou; Monica Giménez Marqués
- Web page: https://patentgrep.com/patent/US20210277042A1

## CPC

- C07F 15/025: {without a metal-carbon linkage}
- C07F 5/069: {without C-aluminium linkages}
- C07F 7/003: {without C-Metal linkages}
- B82Y 40/00: Manufacture or treatment of nanostructures
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present invention relates to low temperature process for preparing nanoparticles of porous crystalline Fe-, Al- or Ti-based MOF carboxylate materials with low polydispersity index, and uses thereof, particularly as catalyst support for carrying out heterogeneously catalyzed chemical reactions, or as gas storage/separation/purification material, or as matrix for encapsulating active principles (medicine, cosmetics).

## Claims

### Claim 1

A microwave-free process for preparing nanoparticles of porous crystalline Fe-, Al- or Ti-based MOF carboxylate material with low polydispersity index, comprising steps of:
A) mixing in an aqueous solvent system:
(i) at least a first inorganic metallic precursor in the form of a metal M, a salt of a metal M or a coordination complex comprising the metal ion M2+ selected from Fe2+, Fe3+, Ti3+, Ti4+ or Al3+;
(ii) at least one precursor ligand L′ different from carboxylate salt and having the structure R1—(C(═O)—R3)q wherein:
q represents an integer from 2 to 6; preferably q represents 2, 3 or 4;
each occurrence of R3 is independently selected from a halogen atom, —OH, —OR4, —O—C(═O)R3A or —NR3AR3B, wherein R3A and R3B, identical or different, represent C1-12 alkyl radicals;
R1 independently represents:
(a) a C1-12alkyl, C2-12alkenyl or C2-12alkynyl radical;
(b) a fused or non-fused monocyclic or polycyclic aryl radical, comprising 6 to 50 carbon atoms;
(c) a fused or non-fused monocyclic or polycyclic heteroaryl, comprising 4 to 50 carbon atoms;
R1 optionally bearing one or more substituents independently selected from
a halogen atom, —OH, —NH2, —NO2 or C1-6alkyl;
each occurrence of R4 independently represents —OH, a halogen atom, or a —OR5, —O—C(═O)R5 or —NR5R5′ moiety, wherein R5 and R5′ independently represent C1-12alkyl; and
B) allowing the mixture obtained in step A) to react at a temperature at least 10° C. below the boiling point temperature of the aqueous solvent system; so as to obtain the said nanoparticles;
wherein the process is carried out in the absence of acid or base additives.

### Claim 2 (depends on 1)

The process of claim 1, wherein L′ is a di-, tri-, tetra- or hexadentate precursor ligand selected from:
wherein R3 is as defined in claim 1,
s represents an integer from 1 to 4,
each occurrence of t independently represents an integer from 1 to 4,
u represents an integer from 1 to 7,
each occurrence of RL1 and RL2 independently represent H, a halogen or a C1 to C6 alkyl, and
each occurrence of RL3 independently represents H, a halogen atom, —OH, —NH2, —NO2 or C1-6alkyl
X represents a covalent bond, C═O, CH2, N═N, NH, O, S, SO2, C═C, —O—(CH2)p—O—, —NH—(CH2)p—NH— or —S—(CH2)p—S— where p represents an integer ranging from 1 to 4; preferably C═O, CH2, N═N, NH, O, S, SO2, —O—(CH2)p—O—, —NH—(CH2)p—NH— or —S—(CH2)p—S—; most preferably C═O, CH2, or N═N;
each occurrence of m independently represents an integer from 1 to 3; and
each occurrence of R1 independently represents H, a halogen atom, OH, NH2, NO2 or a C1-6alkyl, preferably each occurrence of R1 represents H; and
each occurrence of R4 independently represents —OH, a halogen atom, or a —OR5, —O—C(═O)R5 or —NR5R5′ moiety, wherein R5 and R5′ independently represent C1-12alkyl; preferably each occurrence of R1 represents H and each occurrence of R4 represents OH; most preferably X represents CH2 and each occurrence of R1 represents H and each occurrence of R4 represents OH.

### Claim 3 (depends on 1)

The process of claim 1, wherein the precursor ligand L′ is a di-, tri- or tetracarboxylic acid selected from: C2H2(CO2H)2 (fumaric acid), C2H4(CO2H)2 (succinic acid), C3H6(CO2H)2 (glutaric acid), C4H4(CO2H)2 (muconic acid), C4H8(CO2H)2 (adipic acid), C7H14(CO2H)2 (azelaic acid), C5H3S(CO2H)2 (2,5-thiophenedicarboxylic acid), C6H4(CO2H)2 (terephthalic acid), C6H2N2(CO2H)2 (2,5-pyrazine dicarboxylic acid), C10H6(CO2H)2 (naphthalene-2,6-dicarboxylic acid), C12H3(CO2H)2 (biphenyl-4,4′-dicarboxylic acid), C12H3N2(CO2H)2 (azobenzenedicarboxylic acid), C6H3(CO2H)3 (benzene-1,2,4-tricarboxylic acid), C6H3(CO2H)3 (benzene-1,3,5-tricarboxylic acid), C24H15(CO2H)3 (benzene-1,3,5-tribenzoic acid), C6H2(CO2H)4 (benzene-1,2,4,5-tetracarboxylic acid, C10H4(CO2H)4 (naphthalene-2,3,6,7-tetracarboxylic acid), C10H4(CO2H)4 (naphthalene-1,4,5,8-tetracarboxylic acid), C12H6(CO2H)4 (biphenyl-3,5,3′,5′-tetracarboxylic acid); modified analogs selected from 2-aminoterephthalic acid, 2-nitroterephthalic acid, 2-methylterephthalic acid, 2-chloroterephthalic acid, 2-bromoterephthalic acid, 2,5-dihydroxoterephthalic acid, tetrafluoroterephthalic acid, tetramethylterephthalic acid, dimethyl-4,4′-biphenydicarboxylic acid, tetramethyl-4,4′-biphenydicarboxylic acid, dicarboxy-4,4′-biphenydicarboxylic acid, or 2,5-pyrazyne dicarboxylic acid; or ligand derivatives selected from 2,5-diperfluoroterephthalic acid, azobenzene-4,4′-dicarboxylic acid, 3,3′-dichloro-azobenzene-4,4′-dicarboxylic acid, 3,3′-dihydroxo-azobenzene-4,4′-dicarboxylic acid, 3,3′-diperfluoro-azobenzene-4,4′-dicarboxylic acid, 3,5,3′,5′-azobenzene tetracarboxylic acid, 2,5-dimethylterephthalic acid, or perfluoroglutaric acid.

### Claim 4 (depends on 1)

The process claim 1, wherein the inorganic metallic precursor is a Fe3+ salt such as FeCl3, and the precursor ligand L′ is benzene-1,3,5-tricarboxylic acid or benzene-1,2,4-tricarboxylic acid.

### Claim 5 (depends on 1)

The process of claim 1, wherein the inorganic metallic precursor is Fe3+ salt such as FeCl3, and the precursor ligand L′ is benzene-1,2,4,5-tetracarboxylic acid.

### Claim 6 (depends on 1)

The process of claim 1, wherein the aqueous solvent system is H2O, ethanol, isopropanol, dimethyl carbonate, ethylene glycol, ethyl lactate, ethyl acetate, sulfolane, benzyl alcohol or a mixture of two or more thereof, preferably H2O, ethanol, or a mixture thereof, most preferably H2O.

### Claim 7 (depends on 1)

The process of claim 1, wherein the process is carried out in H2O as sole solvent system, at 60° C.±5° C.

### Claim 8 (depends on 1)

The process of claim 1, wherein the process is carried out under 1·105 Pa (ambient pressure conditions).

### Claim 9 (depends on 1)

The process of claim 1, wherein the process is carried out under dilute conditions whereby the inorganic metallic precursor concentration is ≤50 mM, preferably ≤40 mM, preferably ≤30 mM, most preferably ≤25 mM.

### Claim 10 (depends on 1)

The process of claim 1, wherein, in addition to the first inorganic metallic precursor, a second inorganic metallic precursor, in the form of a metal M1, a salt of a metal M1 of formula (I) or a hydroxide or oxide of a metal M1, is added to the reaction mixture;
M1Yp.nH2O (I)
wherein M1 is a metal selected from Cu, Fe, Co, Ni, Al, Ti, Mn, V, Cr, Ru, Sn or Nb;
Y represents Cl−, NO3−, SO42−, AcO−, or
preferably the other metallic inorganic precursor is in the form of a salt of Cu2+, Fe2+, Fe3+, Co2+, Co3+, Ni2+, Al3+, Ti3+, Ti4+, Mn2+, Mn3+, Mn4+, V3+, V4+, Cr3+, Ru3+, Ru4+, Sn4+, Mg2+, Nb4+ or Nb5+; most preferably the other metallic inorganic precursor is a metal salt such as RuCl3, VCl3, SnCl4, CrCl3 or FeCl3.

### Claim 11 (depends on 1)

The process of claim 1, wherein the process is carried in the presence of particles of iron oxide, preferably nanoparticles of iron oxide, to produce core-shell particles, preferably nanoparticles, where the iron oxide core is encapsulated within a MOF shell.

### Claim 12 (depends on 1)

The process of claim 1, wherein the process leads to nanoparticles of average size <90 nm, preferably <85 nm, preferably <80 nm, preferably <75 nm, most preferably <70 nm.

### Claim 13 (depends on 1)

The process of claim 1, wherein the process leads to nanoparticles having a polydispersity index 0.05≤PDI≤0.5, preferably 0.05≤PDI≤0.4, most preferably 0.05≤PDI≤0.3, as calculated under ISO standard 13321:1996 E and ISO 22412:2008.

### Claim 14 (depends on 1)

A process according to claim 1, further comprising a step of introducing at least one pharmaceutically active ingredient into said porous MOF material.

### Claim 15

Nanoparticles of porous crystalline Fe-, Al- or Ti-based MOF carboxylate material having a polydispersity index 0.05≤PDI≤0.5, preferably 0.05≤PDI≤0.4, most preferably 0.05≤PDI≤0.3, as calculated under ISO standard 13321:1996 E and ISO 22412:2008; and an average size <90 nm, preferably <85 nm, preferably <80 nm, preferably <75 nm, most preferably <70 nm.

### Claim 16 (depends on 15)

A medicament comprising Nanoparticles according to claim 15 and a pharmaceutically active ingredient.

### Claim 17 (depends on 1)

Nanoparticles of porous crystalline MOF carboxylate material obtainable by a process according to claim 1, wherein the MOF carboxylate material:
(i) has the formula Fe3O(H2O)2(OH)4(H2—BTeC)1.5 and is composed of a three-dimensional succession of building units connected through benzene-1,2,4,5-tetracarboxylate linkers; or
(ii) has the formula Fe(OH)(1,2,4-BTC) and is composed of a three-dimensional succession of building units connected through benzene-1,2,4,-tricarboxylate linkers.

### Claim 18 (depends on 11)

A medical imaging marker comprising Nanoparticles obtainable by a process according to claim 11.

### Claim 19 (depends on 10)

A catalyst support for carrying out heterogeneously catalyzed chemical reactions comprising nanoparticles obtainable by a process according to claim 10.

### Claim 20 (depends on 1)

A catalyst support for carrying out heterogeneously catalyzed chemical reactions, a gas storage/separation/purification material, or a matrix for encapsulating active pharmaceutically active principles, compounds of cosmetic interest or medical imaging markers comprising nanoparticles obtainable by a process according to claim 1.
